Skip to main content
. 2009 Jun 30;101(2):238–243. doi: 10.1038/sj.bjc.6605167

Table 4. Progression-free survival: indirect comparison of sunitinib vs bevacizumab plus IFN.

Comparison Input data HR (95% CI) P-value
Sunitinib vs IFN Motzer: HR=0.538; SE[ln(HR)]=0.103 0.538 (0.439, 0.658) <0.0001*
Bevacizumab vs IFN {AVOREN: HR=0.630; SE[ln(HR)]=0.093 CALGB: HR=0.710; SE[ln(HR)]=0.079} 0.676 (0.601, 0.760) <0.0001*
Sunitinib vs bevacizumab [Indirect comparison] 0.796 (0.630, 1.004) 0.0272*

Abbreviations: HR=hazard ratio; IFN=interferon.

Based on 100 000 MCMC iterations.*One-tailed P-values.